Receptor-Mediated Drug Delivery Systems Targeting to Glioma
Glioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radi...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-12-01
|
Series: | Nanomaterials |
Subjects: | |
Online Access: | http://www.mdpi.com/2079-4991/6/1/3 |
id |
doaj-244ba754fb194e1ab2bb7e841c899f71 |
---|---|
record_format |
Article |
spelling |
doaj-244ba754fb194e1ab2bb7e841c899f712020-11-25T01:09:40ZengMDPI AGNanomaterials2079-49912015-12-0161310.3390/nano6010003nano6010003Receptor-Mediated Drug Delivery Systems Targeting to GliomaShanshan Wang0Ying Meng1Chengyi Li2Min Qian3Rongqin Huang4Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, ChinaGlioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radiotherapy, and chemotherapy. This provides a rationale for the development of some novel therapeutic strategies. Among them, receptor-mediated drug delivery is a specific pattern taking advantage of differential expression of receptors between tumors and normal tissues. The strategy can actively transport drugs, such as small molecular drugs, gene medicines, and therapeutic proteins to glioma while minimizing adverse reactions. This review will summarize recent progress on receptor-mediated drug delivery systems targeting to glioma, and conclude the challenges and prospects of receptor-mediated glioma-targeted therapy for future applications.http://www.mdpi.com/2079-4991/6/1/3gliomablood-brain barrier (BBB)receptor-mediatedsingle ligand-modified targeting systemsdual ligand-modified targeting systems |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shanshan Wang Ying Meng Chengyi Li Min Qian Rongqin Huang |
spellingShingle |
Shanshan Wang Ying Meng Chengyi Li Min Qian Rongqin Huang Receptor-Mediated Drug Delivery Systems Targeting to Glioma Nanomaterials glioma blood-brain barrier (BBB) receptor-mediated single ligand-modified targeting systems dual ligand-modified targeting systems |
author_facet |
Shanshan Wang Ying Meng Chengyi Li Min Qian Rongqin Huang |
author_sort |
Shanshan Wang |
title |
Receptor-Mediated Drug Delivery Systems Targeting to Glioma |
title_short |
Receptor-Mediated Drug Delivery Systems Targeting to Glioma |
title_full |
Receptor-Mediated Drug Delivery Systems Targeting to Glioma |
title_fullStr |
Receptor-Mediated Drug Delivery Systems Targeting to Glioma |
title_full_unstemmed |
Receptor-Mediated Drug Delivery Systems Targeting to Glioma |
title_sort |
receptor-mediated drug delivery systems targeting to glioma |
publisher |
MDPI AG |
series |
Nanomaterials |
issn |
2079-4991 |
publishDate |
2015-12-01 |
description |
Glioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radiotherapy, and chemotherapy. This provides a rationale for the development of some novel therapeutic strategies. Among them, receptor-mediated drug delivery is a specific pattern taking advantage of differential expression of receptors between tumors and normal tissues. The strategy can actively transport drugs, such as small molecular drugs, gene medicines, and therapeutic proteins to glioma while minimizing adverse reactions. This review will summarize recent progress on receptor-mediated drug delivery systems targeting to glioma, and conclude the challenges and prospects of receptor-mediated glioma-targeted therapy for future applications. |
topic |
glioma blood-brain barrier (BBB) receptor-mediated single ligand-modified targeting systems dual ligand-modified targeting systems |
url |
http://www.mdpi.com/2079-4991/6/1/3 |
work_keys_str_mv |
AT shanshanwang receptormediateddrugdeliverysystemstargetingtoglioma AT yingmeng receptormediateddrugdeliverysystemstargetingtoglioma AT chengyili receptormediateddrugdeliverysystemstargetingtoglioma AT minqian receptormediateddrugdeliverysystemstargetingtoglioma AT rongqinhuang receptormediateddrugdeliverysystemstargetingtoglioma |
_version_ |
1725177336995774464 |